EBS Quote, Financials, Valuation and Earnings

Moderna, Inc. has a net margin of -8.52% compared to Emergent BioSolutions, Inc.'s net margin of -580.99%. Emergent BioSolutions, Inc.'s return on equity of 28.28% beat Moderna, Inc.'s return on equity of -26.88%.

Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 62.65%. On the other hand Moderna, Inc. has an analysts' consensus of $45.45 which suggests that it could grow by 88.67%. Given that Moderna, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Moderna, Inc. is more attractive than Emergent BioSolutions, Inc..

Emergent BioSolutions, Inc. has a beta of 2.038, which suggesting that the stock is 103.814% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.928, suggesting its more volatile than the S&P 500 by 92.77%.

Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Emergent BioSolutions, Inc. quarterly revenues are $140.9M, which are smaller than Moderna, Inc. quarterly revenues of $142M. Emergent BioSolutions, Inc.'s net income of -$12M is higher than Moderna, Inc.'s net income of -$825M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 3.39x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.54x versus 3.05x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -8.52% compared to Emergent BioSolutions, Inc.'s net margin of -49.65%. Emergent BioSolutions, Inc.'s return on equity of 28.28% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -364.55%.

Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 62.65%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -52.25%. Given that Emergent BioSolutions, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Emergent BioSolutions, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Emergent BioSolutions, Inc. has a beta of 2.038, which suggesting that the stock is 103.814% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.692%.

Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Emergent BioSolutions, Inc. quarterly revenues are $140.9M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of -$12M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$2M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 3.39x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.54x versus 1.86x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -8.52% compared to Emergent BioSolutions, Inc.'s net margin of 19.81%. Emergent BioSolutions, Inc.'s return on equity of 28.28% beat Pfizer Inc.'s return on equity of 12%.

Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 62.65%. On the other hand Pfizer Inc. has an analysts' consensus of $28.77 which suggests that it could grow by 16.21%. Given that Emergent BioSolutions, Inc. has higher upside potential than Pfizer Inc., analysts believe Emergent BioSolutions, Inc. is more attractive than Pfizer Inc..

Emergent BioSolutions, Inc. has a beta of 2.038, which suggesting that the stock is 103.814% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.553, suggesting its less volatile than the S&P 500 by 44.747%.

Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out -118.15% of its earnings as a dividend.

Emergent BioSolutions, Inc. quarterly revenues are $140.9M, which are smaller than Pfizer Inc. quarterly revenues of $14.7B. Emergent BioSolutions, Inc.'s net income of -$12M is lower than Pfizer Inc.'s net income of $2.9B. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 3.39x while Pfizer Inc.'s PE ratio is 13.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.54x versus 2.21x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -8.52% compared to Emergent BioSolutions, Inc.'s net margin of --. Emergent BioSolutions, Inc.'s return on equity of 28.28% beat Theriva Biologics, Inc.'s return on equity of -151.61%.

Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 62.65%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 1607.32%. Given that Theriva Biologics, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Emergent BioSolutions, Inc..

Emergent BioSolutions, Inc. has a beta of 2.038, which suggesting that the stock is 103.814% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28.008%.

Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Emergent BioSolutions, Inc. quarterly revenues are $140.9M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of -$12M is higher than Theriva Biologics, Inc.'s net income of -$13.1M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 3.39x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.54x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.